We are live on ! Find out more
DICE

DICE Therapeutics, Inc. Common Stock

Delisted

DICE was delisted on the 8th of August, 2023.

69 hedge funds and large institutions have $799M invested in DICE Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

344% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 9

77% more funds holding

Funds holding: 3969 (+30)

50% more funds holding in top 10

Funds holding in top 10: 46 (+2)

1% more capital invested

Capital invested by funds: $794M → $799M (+$5.71M)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

Holders
69
Holders Change
+30
Holders Change %
+76.92%
% of All Funds
1.06%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
40
Increased
9
Reduced
10
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SRC
76
Samson Rock Capital
United Kingdom
-$240K -7,333 Closed
Qube Research & Technologies (QRT)
77
Qube Research & Technologies (QRT)
United Kingdom
-$222K -6,788 Closed
PHK
78
Point72 Hong Kong
Hong Kong
-$203K -6,205 Closed

DICE Hedge Fund Activity: Q4 2021 in Review

69 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in DICE Therapeutics, Inc. Common Stock (DICE) for Q4 2021, worth a combined $799M — up 0.72% from $794M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new DICE positions and 9 closed out — a net gain of 31 holders — while 9 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $25.1M. The largest seller was Fidelity Investments, cutting an estimated $16.8M.

  • 69 institutional investors held DICE Therapeutics, Inc. Common Stock (DICE) as of Q4 2021, up from 39 in Q3 2021.
  • Funds reported $799M of DICE Therapeutics, Inc. Common Stock stock for Q4 2021, up 0.72% quarter-over-quarter.
  • 40 funds opened new DICE Therapeutics, Inc. Common Stock positions in Q4 2021 and 9 closed out, a net change of +31 holders.
  • The largest DICE Therapeutics, Inc. Common Stock buyer in Q4 2021 was BlackRock, an estimated $25.1M added.
  • The largest DICE Therapeutics, Inc. Common Stock seller in Q4 2021 was Fidelity Investments, an estimated $16.8M sold.

Based on aggregated 13F filings for Q4 2021.